Status:
COMPLETED
Outcomes of Prophylaxis With Emicizumab in Children With Severe Hemophilia A in Ivory Coast
Lead Sponsor:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Conditions:
Hemophilia A
Eligibility:
MALE
2-18 years
Phase:
NA
Brief Summary
Assessment of the outcomes of prophylaxis with Emicizumab in children with severe hemophilia A in Ivory Coast
Detailed Description
Assessment of the outcomes of prophylaxis with Emicizumab in children with severe hemophilia A in Ivory Coast. Duration of the study: 1 year after initiation of prophylaxis with Emicizumab Inclusion...
Eligibility Criteria
Inclusion
- severe hemophilia A with or without inhibitors -
Exclusion
- parents refusal
- \-
Key Trial Info
Start Date :
July 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 20 2022
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT05279924
Start Date
July 1 2021
End Date
October 20 2022
Last Update
October 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Yopougon
Abidjan, Côte d’Ivoire